Qualifying Notice - Avastin

This Notice of Compliance with Conditions Qualifying Notice (NOC/c-QN), issued in accordance with the Health Canada NOC/c Policy, is to advise you that information submitted in support of the Supplement to a New Drug Submission for Avastin (bevacizumab), Control Number 130719, for the indication as a single agent for the treatment of patients with glioblastoma after relapse or disease progression following prior therapy, qualifies to be considered for authorization under the NOC/c Policy. Read more here.